ETF Holdings Breakdown of EXEL

Stock NameExelixis Inc
TickerEXEL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS30161Q1040

News associated with EXEL

Exelixis Reaches Analyst Target Price
In recent trading, shares of Exelixis Inc (Symbol: EXEL) have crossed above the average analyst 12-month target price of $37.15, changing hands for $37.21/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati - 2025-04-25 11:00:40
Barclays PLC Increases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Barclays PLC grew its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 8.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 348,009 shares of the biotechnology company’s stock after buying an additional 28,420 shares during the period. Barclays PLC […] - 2025-04-22 08:47:07
Exelixis, Inc. (NASDAQ:EXEL) Receives $37.59 Average Target Price from Brokerages
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the twenty brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company. […] - 2025-04-18 05:28:59
Bank of Montreal Can Has $3.13 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)
Bank of Montreal Can cut its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.0% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 93,921 shares of the biotechnology company’s stock after selling 10,464 shares during the quarter. Bank of Montreal Can’s holdings in Exelixis were worth $3,128,000 as of its most recent […] - 2025-04-16 08:31:00
Fmr LLC Has $98.16 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Fmr LLC lifted its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 19.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,947,599 shares of the biotechnology company’s stock after buying an additional 485,527 shares during the quarter. Fmr […] - 2025-04-16 07:34:56
Cerity Partners LLC Buys 45,890 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Cerity Partners LLC grew its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 163.9% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 73,884 shares of the biotechnology company’s stock after acquiring an additional 45,890 shares during the quarter. Cerity Partners LLC’s […] - 2025-04-16 07:34:54
LPL Financial LLC Acquires 22,370 Shares of Exelixis, Inc. (NASDAQ:EXEL)
LPL Financial LLC lifted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 26.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 107,212 shares of the biotechnology company’s stock after acquiring an additional 22,370 shares during the quarter. LPL Financial LLC’s […] - 2025-04-11 07:50:51
Alliancebernstein L.P. Sells 14,245 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Alliancebernstein L.P. lessened its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.5% during the fourth quarter, HoldingsChannel reports. The firm owned 390,775 shares of the biotechnology company’s stock after selling 14,245 shares during the period. Alliancebernstein L.P.’s holdings in Exelixis were worth $13,013,000 as of its most recent filing with the Securities and […] - 2025-04-10 08:28:58
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. lowered its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 25.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,314,575 shares of the biotechnology company’s stock after selling 1,116,078 shares during the quarter. JPMorgan Chase […] - 2025-04-03 09:09:17
American Century Companies Inc. Sells 47,750 Shares of Exelixis, Inc. (NASDAQ:EXEL)
American Century Companies Inc. cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 415,865 shares of the biotechnology company’s stock after selling 47,750 shares during the quarter. American Century Companies […] - 2025-04-02 08:24:55
Mitsubishi UFJ Trust & Banking Corp Reduces Stock Position in Exelixis, Inc. (NASDAQ:EXEL)
Mitsubishi UFJ Trust & Banking Corp trimmed its holdings in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 3.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 92,009 shares of the biotechnology company’s stock after selling 3,657 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp’s holdings in Exelixis were worth $3,064,000 […] - 2025-04-01 07:58:53
Thrivent Financial for Lutherans Reduces Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Thrivent Financial for Lutherans reduced its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 74,233 shares of the biotechnology company’s stock after selling 1,451 shares during the quarter. Thrivent Financial for Lutherans’ holdings in […] - 2025-03-28 08:28:50
Corient Private Wealth LLC Has $1.52 Million Position in Exelixis, Inc. (NASDAQ:EXEL)
Corient Private Wealth LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 111.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 45,799 shares of the biotechnology company’s stock after acquiring an additional 24,108 shares during the quarter. Corient Private […] - 2025-03-26 08:40:47
Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have assigned a buy recommendation to […] - 2025-03-26 06:57:00
Natixis Advisors LLC Buys 31,737 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Natixis Advisors LLC grew its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 109.0% in the fourth quarter, Holdings Channel reports. The fund owned 60,850 shares of the biotechnology company’s stock after acquiring an additional 31,737 shares during the quarter. Natixis Advisors LLC’s holdings in Exelixis were worth $2,026,000 at the end of the […] - 2025-03-25 07:56:50
Exelixis, Inc. (NASDAQ:EXEL) Stake Trimmed by Commonwealth Equity Services LLC
Commonwealth Equity Services LLC cut its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 1.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 139,217 shares of the biotechnology company’s stock after selling 2,044 shares during the quarter. Commonwealth Equity Services […] - 2025-03-24 07:57:06
SCHA, ITCI, AFRM, EXEL: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Small-Cap ETF (Symbol: SCHA) where we have detected an approximate $550.8 million dollar outflow -- that's a 3.3% decrease week over week - 2025-03-17 14:52:32
Zurcher Kantonalbank Zurich Cantonalbank Increases Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)
Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 5.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 63,447 shares of the biotechnology company’s stock after purchasing an additional 3,349 shares during the quarter. Zurcher Kantonalbank […] - 2025-03-17 08:18:58
Exelixis Reaches Analyst Target Price
In recent trading, shares of Exelixis Inc (Symbol: EXEL) have crossed above the average analyst 12-month target price of $37.05, changing hands for $37.18/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuati - 2025-03-13 11:00:04
Oppenheimer & Co. Inc. Takes $561,000 Position in Exelixis, Inc. (NASDAQ:EXEL)
Oppenheimer & Co. Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 16,836 shares of the biotechnology company’s stock, valued at approximately $561,000. Other hedge funds also recently modified their holdings of the […] - 2025-03-07 09:07:09
Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Truist Financial Corp
Truist Financial Corp grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,169 shares of the biotechnology company’s stock after purchasing an additional 4,378 shares during the quarter. Truist Financial Corp’s […] - 2025-03-03 08:20:57
New York State Common Retirement Fund Trims Holdings in Exelixis, Inc. (NASDAQ:EXEL)
New York State Common Retirement Fund reduced its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 10.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 157,257 shares of the biotechnology company’s stock after selling 18,460 shares during the quarter. New York […] - 2025-02-28 09:04:55
Analysts Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $37.24
Shares of Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the twenty analysts that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the […] - 2025-02-27 06:22:51
CIBC Asset Management Inc Has $307,000 Stake in Exelixis, Inc. (NASDAQ:EXEL)
CIBC Asset Management Inc boosted its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 5.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,210 shares of the biotechnology company’s stock after purchasing an additional 452 shares during the […] - 2025-02-25 08:42:59
Principal Financial Group Inc. Has $22.06 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)
Principal Financial Group Inc. reduced its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 662,436 shares of the biotechnology company’s stock after selling 3,306 shares during the period. Principal Financial […] - 2025-02-24 08:49:13
Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Rhumbline Advisers
Rhumbline Advisers lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 827,114 shares of the biotechnology company’s stock after selling 5,657 shares during the period. Rhumbline Advisers’ holdings in Exelixis were worth […] - 2025-02-20 08:54:51
Blue Trust Inc. Purchases 5,137 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Blue Trust Inc. grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 84.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 11,231 shares of the biotechnology company’s stock after acquiring an additional 5,137 shares during the quarter. Blue Trust Inc.’s holdings in Exelixis […] - 2025-02-19 10:12:49
Short Interest in Exelixis, Inc. (NASDAQ:EXEL) Declines By 9.5%
Exelixis, Inc. (NASDAQ:EXEL – Get Free Report) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 13,090,000 shares, a decline of 9.5% from the January 15th total of 14,460,000 shares. Approximately 4.7% of the shares of the stock are short sold. Based on an average daily […] - 2025-02-19 06:31:00
Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by V Square Quantitative Management LLC
V Square Quantitative Management LLC increased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 37.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,563 shares of the biotechnology company’s stock after buying an additional 425 […] - 2025-02-18 09:29:07
Van ECK Associates Corp Buys 78,740 Shares of Exelixis, Inc. (NASDAQ:EXEL)
Van ECK Associates Corp lifted its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 45.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 252,324 shares of the biotechnology company’s stock after purchasing an additional 78,740 shares during the period. Van ECK Associates […] - 2025-02-17 08:52:26

EXEL institutional holdings

The following institutional investment holdings of EXEL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 168,406USD 6,146,819
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 26,733USD 975,755 -0.8%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 393,580USD 14,365,670
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 133,230USD 4,862,895
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 133,230USD 4,862,895 -0.8%
2025-05-08 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 2,495USD 91,068 -0.8%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 591USD 21,572
2025-05-08 IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF) 642USD 23,433
2024-12-10 IE000KJPDY61 (iShares World Equity High Income UCITS ETF USD Inc) 508USD 17,897 0.2%
2025-04-29 IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc) 6 -3,716.7%USD 231 -3,710.8%
Total =859,421 USD 31,368,235
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.